SCOLR’s sales drop
This article was originally published in The Tan Sheet
Executive Summary
Revenues for the first quarter declined 76 percent to $265,555 for Bellevue, Wash.-based SCOLR Pharma, the firm announces May 2. The firm credits the previous year's higher revenues during the January-March period to $795,000 of research and development fees and licensing revenues from a terminated license agreement. Wyeth terminated a licensing agreement to use SCOLR's controlled delivery technology in OTC formulations (1"The Tan Sheet" March 19, 2007, p. 13). However, SCOLR is optimistic about its development of ibuprofen and pseudoephedrine formulas, its "lead product candidates." The firm this year announced the completion of two drug trials and plans for a 12-hour release of an OTC ibuprofen product (2"The Tan Sheet" March 24, 2008, In Brief)...
You may also be interested in...
SCOLR May File NDA For Ibuprofen Product Following Break With Wyeth
SCOLR Pharma will either file an NDA with FDA or work with another pharmaceutical company to develop its 12-hour extended-release ibuprofen product after Wyeth announced it will terminate an agreement with the firm effective April 16
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.